In the original article, there was an error. “Allopregnanolone, today best known as brexanolone and marketed as Zulresso™ for the treatment of postpartum depression is part of only two recently Food and Drug Administration (FDA)-approved fast-acting antidepressants, with esketamine nasal spray, an NMDA receptor antagonist used in treatment-resistant depression with suicidality being the other.” However, SPRAVATO®(esketamine) CIII Nasal Spray was approved by the FDA last year to treat treatment-resistant depression in adults when used along with an oral antidepressant, and is not indicated for the treatment of suicidality.
A correction has been made to the Introduction section, First paragraph:
“Allopregnanolone, today best known as brexanolone and marketed as Zulresso™ for the treatment of postpartum depression is part of only two recently Food and Drug Administration (FDA)-approved fast-acting antidepressants, with esketamine nasal spray, an NMDA receptor antagonist used in treatment-resistant depression being the other (1).”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Summary
Keywords
brexanolone, allopregnanolone (3α, 5α-THP), postpartum depression, fast-acting antidepressant, GABAA receptor, 5α-reduced steroids, 5α-reductase, 3α-HSD
Citation
Pinna G (2020) Corrigendum: Allopregnanolone, the Neuromodulator Turned Therapeutic Agent: Thank You, Next?. Front. Endocrinol. 11:507. doi: 10.3389/fendo.2020.00507
Received
11 June 2020
Accepted
24 June 2020
Published
30 July 2020
Approved by
Hubert Vaudry, Université de Rouen, France
Volume
11 - 2020
Updates
Copyright
© 2020 Pinna.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Graziano Pinna gpinna@uic.edu; graziano_pinna@yahoo.com
This article was submitted to Neuroendocrine Science, a section of the journal Frontiers in Endocrinology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.